Methylene blue

Generic Name
Methylene blue
Brand Names
Hyophen, Phosphasal, Provayblue, Proveblue, Urelle, Uribel, Urimar Reformulated Oct 2013, Urin DS, Urogesic Blue Reformulated Apr 2012, Ustell, Utira, Lumeblue (previously known as Methylthioninium chloride Cosmo), Methylthioninium chloride Proveblue
Drug Type
Small Molecule
Chemical Formula
C16H18ClN3S
CAS Number
61-73-4
Unique Ingredient Identifier
8NAP7826UB
Background

Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinar...

Indication

Indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
...

Associated Conditions
Cystitis, Methemoglobinemia, Nephritis, Urethritis, Urinary tract inflammation
Associated Therapies
Diuresis
Clinical Trials
Related News

The Effect of Methylene Blue Infiltrating Injection on Anal Pain After Milligan-Morgan Surgery: a Randomized Controlled Clinical Study

Phase 3
Conditions
Mixed Hemorrhoids
Interventions
Drug: Methylene Blue
First Posted Date
2024-10-28
Last Posted Date
2024-10-28
Lead Sponsor
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Target Recruit Count
60
Registration Number
NCT06660680
Locations
🇨🇳

Second hospital affiliated Anhui University of Chinese Medicine, Hefei, Anhui, China

Methylene Blue for the Treatment of Septic Shock

Phase 3
Recruiting
Conditions
Septic Shock
Interventions
Drug: Methylene Blue
Drug: Placebo
First Posted Date
2024-08-01
Last Posted Date
2024-08-09
Lead Sponsor
Northern Jiangsu People's Hospital
Target Recruit Count
76
Registration Number
NCT06532240
Locations
🇨🇳

Northern Jiangsu people's hospital, Yangzhou, Jiangsu, China

Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock

Phase 2
Not yet recruiting
Conditions
Neonatal Sepsis
Shock, Septic
Interventions
Other: Placebo
Drug: Methylene Blue
First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
130
Registration Number
NCT06306001
Locations
🇮🇳

Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

First Posted Date
2023-09-25
Last Posted Date
2024-05-16
Lead Sponsor
University of Rochester
Target Recruit Count
90
Registration Number
NCT06052956
Locations
🇺🇸

Highland Hospital, Rochester, New York, United States

🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.

Completed
Conditions
Breast Cancer
First Posted Date
2023-09-06
Last Posted Date
2024-05-10
Lead Sponsor
BTG International Inc.
Target Recruit Count
101
Registration Number
NCT06024213
Locations
🇫🇷

Hôpital Européen Georges-Pompidou Paris, Paris, Île-de-France, France

🇫🇷

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

🇫🇷

CHU de Saint-Etienne, Saint-Etienne, Loire, France

and more 3 locations

The Effect of Combination Therapy of Oral MB and PRP-FG in Patients With Non-healing Diabetic Foot Ulcer

First Posted Date
2023-05-09
Last Posted Date
2023-10-04
Lead Sponsor
Mashhad University of Medical Sciences
Target Recruit Count
20
Registration Number
NCT05850611
Locations
🇮🇷

Mashhad University of Medical Sciences, Mashhad, Razavi Khorasan, Iran, Islamic Republic of

Methylene Blue for the Prevention of Hypotension During Hemodialysis

Phase 2
Recruiting
Conditions
Shock
Acute Kidney Injury
Interventions
Other: Control
Drug: Methylene Blue
First Posted Date
2021-10-25
Last Posted Date
2024-02-26
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
260
Registration Number
NCT05092165
Locations
🇧🇷

Federal University of São Paulo, São Paulo, Brazil

COVID-19 Methylene Blue Antiviral Treatment

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Saline nasal spray
Drug: Methylene Blue
First Posted Date
2021-08-13
Last Posted Date
2022-02-09
Lead Sponsor
Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences
Target Recruit Count
24
Registration Number
NCT05004805
Locations
🇷🇺

Irkutsk Regional Hospital, Irkutsk, Irkutskaya Oblast, Russian Federation

The Effect of Early Use of Methylene Blue on Hemodynamics in Septic Shock

Not Applicable
Conditions
Septic Shock
Interventions
Drug: Methylene Blue
First Posted Date
2021-07-21
Last Posted Date
2021-07-21
Lead Sponsor
Xiangya Hospital of Central South University
Target Recruit Count
106
Registration Number
NCT04970602
Locations
🇨🇳

Xiangya Hospital, Central South University, Changsha, Hunan, China

Methylene Blue Treatment of COVID-19

First Posted Date
2020-11-19
Last Posted Date
2022-04-20
Lead Sponsor
Fondazione Epatocentro Ticino
Target Recruit Count
64
Registration Number
NCT04635605
Locations
🇨🇭

Fondazione Epatocentro Ticino, Lugano, Ticino, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy